Company news

Verastem, Inc. news in 2026

Verastem, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026

October 22, 2026

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

October 14, 2026

Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

October 14, 2026

VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)

October 14, 2026

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 5, 2026

Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026

October 2, 2026

Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer

September 28, 2026

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting

September 24, 2026

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

September 8, 2026

Verastem Oncology to Participate in Upcoming September Investor Conferences

September 2, 2026

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

August 6, 2026

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

July 27, 2026

Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

July 23, 2026

Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

July 22, 2026

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

June 22, 2026

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

June 17, 2026

Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer

June 16, 2026

Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program

June 15, 2026

Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

June 3, 2026

Verastem Oncology to Present at Jefferies Healthcare Conference

May 26, 2026

Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

May 26, 2026

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

May 7, 2026

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

April 30, 2026

Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026

April 23, 2026

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers

April 13, 2026

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers

April 9, 2026

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI FAKZYNJA (avutometinib capsules

March 18, 2026

Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

March 16, 2026

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers

March 16, 2026

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

March 4, 2026

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

February 18, 2026

Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

February 4, 2026

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 12, 2026

Calls in 2026

Decks in 2026